Patents by Inventor Alan M. Warshawsky

Alan M. Warshawsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Methyl-Piperidine Compounds Useful for Inhibiting Microsomal Prostaglandin E2 Synthase-1
    Publication number: 20180250282
    Abstract: The present invention provides compounds of Formula 1, or a pharmaceutically acceptable salt thereof, where R, R1, and G are as described herein; methods of preparing the compounds; and use of the compounds to treat pain and/or inflammation associated with arthritis or osteoarthritis.
    Type: Application
    Filed: May 7, 2018
    Publication date: September 6, 2018
    Inventors: Matthew Joseph Fisher, Steven Lee Kuklish, Peter Rudolph Manninen, Katherine Marie Partridge, Matthew Allen Schiffler, Alan M. Warshawsky, Jeremy Schulenburg York
  • Dimethylbenzoic acid compounds
    Patent number: 10005721
    Abstract: The present invention provides a compound of the Formula I: wherein A is: and W, Y, X, R1, R2, R3, and R4 are as defined herein, or a pharmaceutically acceptable salt thereof, for use as an inhibitor of the EP4 receptor.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: June 26, 2018
    Assignee: Eli Lilly and Company
    Inventors: Maria Jesus Blanco-Pillado, Peter Rudolph Manninen, Matthew Allen Schiffler, Tatiana Natali Vetman, Alan M Warshawsky, Jeremy Schulenburg York
  • Methyl-piperidine compounds useful for inhibiting microsomal prostaglandin Esynthase-1
    Patent number: 9962375
    Abstract: The present invention provides compounds of Formula (1), or a pharmaceutically acceptable salt thereof, formula (1), where R, R1, and G are as described herein; methods of preparing the compounds; and use of the compounds to treat pain and/or inflammation associated with arthritis or osteoarthritis.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: May 8, 2018
    Assignee: Eli Lilly and Company
    Inventors: Matthew Joseph Fisher, Steven Lee Kuklish, Peter Rudolph Manninen, Katherine Marie Partridge, Matthew Allen Schiffler, Alan M. Warshawsky, Jeremy Schulenburg York
  • Novel Methyl-Piperidine Compounds Useful for Inhibiting Microsomal Prostaglandin E2 Synthase-1
    Publication number: 20170326128
    Abstract: The present invention provides compounds of Formula (1), or a pharmaceutically acceptable salt thereof, formula (1), where R, R1, and G are as described herein; methods of preparing the compounds; and use of the compounds to treat pain and/or inflammation associated with arthritis or osteoarthritis.
    Type: Application
    Filed: October 22, 2015
    Publication date: November 16, 2017
    Inventors: Matthew Joseph Fisher, Steven Lee Kuklish, Peter Rudolph Manninen, Katherine Marie Partridge, Matthew Allen Schiffler, Alan M. Warshawsky, Jeremy Schulenburg York
  • Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators
    Patent number: 9776964
    Abstract: The present invention provides a compound of the Formula (I): wherein X, R, R1, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined herein, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: October 3, 2017
    Assignee: Eli Lilly and Company
    Inventors: Matthew Joseph Fisher, Steven Lee Kuklish, Peter Rudolph Manninen, Matthew Allen Schiffler, Alan M Warshawsky, Jeremy Schulenburg York
  • Phenoxyethyl Cyclic Amine Derivatives and Their Activity as EP4 Receptor Modulators
    Publication number: 20160272585
    Abstract: The present invention provides a compound of the Formula (I): wherein X, R, R1, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined herein, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 11, 2014
    Publication date: September 22, 2016
    Applicant: ELI LILLY AND COMPANY
    Inventors: Matthew Joseph Fisher, Steven Lee Kuklish, Peter Rudolph Manninen, Matthew Allen Schiffler, Alan M Warshawsky, Jeremy Schulenburg York
  • DIMETHYLBENZOIC ACID COMPOUNDS
    Publication number: 20160251306
    Abstract: The present invention provides a compound of the Formula I: wherein A is: and W, Y, X, R1, R2, R3, and R4 are as defined herein, or a pharmaceutically acceptable salt thereof, for use as an inhibitor of the EP4 receptor.
    Type: Application
    Filed: December 11, 2014
    Publication date: September 1, 2016
    Inventors: Maria Jesus Blanco-Pillado, Peter Rudolph Manninen, Matthew Allen Schiffler, Tatiana Natali Vetman, Alan M Warshawsky, Jeremy Schulenburg York
  • Phenoxyethoxy compounds
    Patent number: 9000043
    Abstract: The present invention provides a compound of the Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: April 7, 2015
    Assignee: Eli Lilly and Company
    Inventors: Peter Rudolph Manninen, Alan M Warshawsky
  • PHENOXYETHOXY COMPOUNDS
    Publication number: 20140235718
    Abstract: The present invention provides a compound of the Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 4, 2014
    Publication date: August 21, 2014
    Applicant: Eli Lilly and Company
    Inventors: Peter Rudolph MANNINEN, Alan M. WARSHAWSKY
  • Compounds and methods for modulating FXR
    Patent number: 8153624
    Abstract: Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: April 10, 2012
    Assignee: Eli Lilly and Company
    Inventors: Michael James Genin, Francisco Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Peter Rudolph Manninen, Alan M. Warshawsky
  • Compounds and methods for modulating FXR
    Patent number: 8106077
    Abstract: Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: January 31, 2012
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Robert Anthony Doti, Matthew Scott Dowling, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Nathan Bryan Mantlo, Jason Matthew Ochoada, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M Warshawsky
  • Vitamin D receptor modulators
    Patent number: 7943795
    Abstract: The present invention relates to novel, non-secosteroidal, phenyl-naphthalene compounds of Formula (I): wherein R, R1, RP, ZP, LP1, LP2 LNP, RP3, RN, and ZNP are defined herein, their preparation, pharmaceutical compositions, and methods of use.
    Type: Grant
    Filed: December 19, 2005
    Date of Patent: May 17, 2011
    Assignee: Eli Lilly and Company
    Inventors: Lynn Stacy Gossett, Jose Eduardo Lopez, Alan M. Warshawsky, Ying Kwong Yee
  • Vitamin D receptor modulators
    Patent number: 7897789
    Abstract: The present invention relates to novel, non-secosteroidal, phenyl-benzothiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.
    Type: Grant
    Filed: July 6, 2009
    Date of Patent: March 1, 2011
    Assignee: Eli Lilly and Company
    Inventors: Jianliang Lu, Tainwei Ma, Sunil Nagpal, Quanrong Shen, Alan M. Warshawsky, Ying Kwong Yee, Michael John Rupp
  • Compounds and methods for modulating FX-receptors
    Patent number: 7863302
    Abstract: Compounds of formula and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: January 4, 2011
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Michael James Genin, Peter Ambrose Lander, Lindsay Scott Stelzer, Robert Anthony Doti, Francisco Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Peter Rudolph Manninen, Jason Matthew Ochoada, Quanrong Shen, Alan M. Warshawsky, Tianwei Ma, Ryan Edward Stites
  • FXR agonists
    Patent number: 7846960
    Abstract: Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: December 7, 2010
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Robert Anthony Doti, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Peter Rudolph Manninen, Jason Matthew Ochoada, Fucheng Qu, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M. Warshawsky
  • COMPOUNDS AND METHODS FOR MODULATING FXR
    Publication number: 20100152166
    Abstract: Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia.
    Type: Application
    Filed: July 11, 2008
    Publication date: June 17, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Michael James Genin, Francisco Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Peter Rudolph Manninen, Alan M. Warshawsky
  • VITAMIN D RECEPTOR MODULATORS
    Publication number: 20100076065
    Abstract: The present invention relates to novel, non-secosteroidal, phenyl-benzothiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.
    Type: Application
    Filed: July 6, 2009
    Publication date: March 25, 2010
    Inventors: Jianliang Lu, Tainwei Ma, Sunil Nagpal, Quanrong Shen, Alan M. Warshawsky, Ying Kwong Yee, Michael John Rupp
  • Vitamin D receptor modulators
    Patent number: 7659296
    Abstract: The present invention relates to novel, non-secosteroidal, phenyl-benzoxazole compounds of Formula (I) wherein the variables R, R?, RP, RP3, LP1, LP2, ZP, RB, RB?, LXB and ZXB are as hereinafter defined, their preparation, pharmaceutical compositions, and methods of use.
    Type: Grant
    Filed: December 19, 2005
    Date of Patent: February 9, 2010
    Assignee: Eli Lilly and Company
    Inventors: Quanrong Shen, Alan M. Warshawsky, Ying Kwong Yee
  • Sulfonamide derivatives as PPAR modulators
    Patent number: 7655641
    Abstract: The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: February 2, 2010
    Assignee: Eli Lilly and Company
    Inventors: Scott Eugene Conner, Lynn Stacy Gossett, Jonathan Edward Green, Winton Dennis Jones, Jr., Nathan Bryan Mantlo, Donald Paul Matthews, Daniel Ray Mayhugh, Daryl Lynn Smith, Jennifer Ann Vance, Xiaodong Wang, Alan M Warshawsky, Leonard Larry Winneroski, Jr., Yanping Xu, Guoxin Zhu
  • FXR AGONISTS
    Publication number: 20090270460
    Abstract: Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Application
    Filed: May 22, 2007
    Publication date: October 29, 2009
    Inventors: Michael Gregory Bell, Robert Anthony Doti, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Peter Rudolph Manninen, Jason Matthew Ochoada, Fucheng Qu, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M. Warshawsky